Teva Pharmaceutical Industries Stock Performance
| TEVJF Stock | USD 18.25 0.00 0.00% |
On a scale of 0 to 100, Teva Pharmaceutical holds a performance score of 4. The entity has a beta of 1.62, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Teva Pharmaceutical will likely underperform. Please check Teva Pharmaceutical's treynor ratio, downside variance, as well as the relationship between the Downside Variance and kurtosis , to make a quick decision on whether Teva Pharmaceutical's existing price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Teva Pharmaceutical Industries are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak forward-looking indicators, Teva Pharmaceutical reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.2 B | |
| Total Cashflows From Investing Activities | 656 M |
Teva |
Teva Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,670 in Teva Pharmaceutical Industries on June 10, 2024 and sell it today you would earn a total of 155.00 from holding Teva Pharmaceutical Industries or generate 9.28% return on investment over 90 days. Teva Pharmaceutical Industries is currently producing 0.257% returns and takes up 4.8823% volatility of returns over 90 trading days. Put another way, 43% of traded pink sheets are less volatile than Teva, and 95% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Teva Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Teva Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Teva Pharmaceutical Industries, and traders can use it to determine the average amount a Teva Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0526
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TEVJF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.88 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Teva Pharmaceutical is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Teva Pharmaceutical by adding it to a well-diversified portfolio.
Teva Pharmaceutical Fundamentals Growth
Teva Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Teva Pharmaceutical, and Teva Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Teva Pink Sheet performance.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.75 B | |||
| Shares Outstanding | 1.11 B | |||
| Price To Earning | 14.56 X | |||
| Price To Book | 1.10 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 14.93 B | |||
| EBITDA | (1.68 B) | |||
| Cash And Equivalents | 2.06 B | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 19.1 B | |||
| Debt To Equity | 2.28 % | |||
| Book Value Per Share | 7.11 X | |||
| Cash Flow From Operations | 1.59 B | |||
| Earnings Per Share | (0.56) X | |||
| Total Asset | 44.01 B | |||
| Retained Earnings | 14.99 B | |||
| Current Asset | 17.39 B | |||
| Current Liabilities | 19.29 B | |||
About Teva Pharmaceutical Performance
By analyzing Teva Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into Teva Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Teva Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Teva Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel. TEVA PHARMACEUTICAL is traded on OTC Exchange in the United States.Things to note about Teva Pharmaceutical performance evaluation
Checking the ongoing alerts about Teva Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Teva Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Teva Pharmaceutical had very high historical volatility over the last 90 days | |
| The company reported the revenue of 14.93 B. Net Loss for the year was (2.41 B) with profit before overhead, payroll, taxes, and interest of 6.97 B. |
- Analyzing Teva Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Teva Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Teva Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Teva Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Teva Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Teva Pharmaceutical's pink sheet. These opinions can provide insight into Teva Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Teva Pink Sheet analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |